Literature DB >> 7065270

Fibronectin deficiency and intestinal transvascular fluid balance during bacteremia.

B C Dillon, T M Saba.   

Abstract

Reticuloendothelial (RE) clearance dysfunction, which can be induced by opsonic fibronectin deficiency, has been correlated with organ failure during sepsis. We investigate the role of opsonic fibronectin deficiency and RE blockade in modulating alterations in intestinal transvascular fluid balance induced by Pseudomonas bacteremia using an isolated, innervated, and autoperfused canine small intestinal segment. Intravenous infusion of gelatin-coated particles was used to induce fibronectin deficiency and RE blockade. Lymph flow and lymph/plasma (L/P) protein concentration ratios were stable following intravenous challenge with bacteria or gelatin-coated particles. In contrast, lymph flow increased and L/P ratio decreased significantly when bacteremia coexisted with particle-induced opsonic fibronectin deficiency and RE blockade. This elevation in lymph flow and decline in L/P ratio was associated with normal vascular permeability to albumin, IgG, and IgM. The increase in intestinal fluid flux during bacteremia with RE blockade appears to be due to an increase in microvascular hydrostatic pressure and not to an increase in vascular permeability. These findings emphasize a potentially important role for fibronectin and associated RE system function as determinants of fluid filtration during sepsis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7065270     DOI: 10.1152/ajpheart.1982.242.4.H557

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  A study on content and distribution of plasma and tissue fibronectin in rats using ELISA and immunofluorescence.

Authors:  H M Jin
Journal:  J Tongji Med Univ       Date:  1990

2.  Plasma fibronectin and associated variables in surgical intensive care patients.

Authors:  E Rubli; S Büssard; E Frei; P Lundsgaard-Hansen; E Pappova
Journal:  Ann Surg       Date:  1983-03       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.